https://orcid.org/0000-0002-8370-9562
References
- Joshi SR, Mittra S, Raj P, et al. Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective. Expert Opin Biol Ther. 2023 Aug;23(8):693–704. doi: 10.1080/14712598.2022.2112664
- Alten R, Weinbrecht-Mischkewitz M. Maximizing the success of biosimilar implementation. Nat Rev Rheumatol. 2023;19(12):757–758. doi: 10.1038/s41584-023-01048-7
- Deng W, Hu J, Yang S, et al. A multicenter real-world study comparing the clinical equivalence of trastuzumab biosimilar HLX02 and reference trastuzumab in the treatment of HER-2-positive breast cancer. Am J Cancer Res. 2023;13(7):3113–3122.
- Giuliani J, Bonetti A. The economic impact of biosimilars in oncology and hematology: the case of Trastuzumab and Rituximab. Anticancer Res. 2019 Jul;39(7):3971–3973. doi: 10.21873/anticanres.13552
- Liu Y, Yang M, Garg V, et al. Economic impact of non-medical switching from originator biologics to Biosimilars: a systematic literature review. Adv Ther. 2019 Aug;36(8):1851–1877. doi: 10.1007/s12325-019-00998-3
- Maini L, Feng J, Hwang T, et al. Biosimilar entry and the pricing of biologic drugs. SSRN J. 2021. doi: http://dx.doi.org/10.2139/ssrn.3760213
- E. Commission, E. H. and D. E. Agency, Vogler S, Salcher-Konrad M, et al., Study on best practices in the public procurement of medicines – Final report. Publications Office of the European Union, 2022. doi: 10.2925/044781.
- Carl DL, Laube Y, Serra-Burriel M, et al. Comparison of uptake and prices of biosimilars in the US, Germany, and Switzerland. JAMA Netw Open. 2022;5(12):e2244670–e2244670. doi: 10.1001/jamanetworkopen.2022.44670
- Vogler S, Schneider P, Zuba M, et al. Policies to encourage the use of biosimilars in European Countries and their potential impact on pharmaceutical expenditure. Front Pharmacol. 2021;12:625296. doi: 10.3389/fphar.2021.625296
- Barcina Lacosta T, Vulto AG, Huys I, et al. An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain. Front Med. 2023;9:1029040. doi: 10.3389/fmed.2022.1029040
- Simoens S, Vulto AG. A health economic guide to market access of biosimilars. Expert Opin Biol Ther. 2021 Jan;21(1):9–17. doi: 10.1080/14712598.2021.1849132
- Simoens S, Jacobs I, Popovian R, et al. Assessing the value of Biosimilars: a review of the role of budget impact analysis. PharmacoEconomics. 2017 Oct;35(10):1047–1062. doi: 10.1007/s40273-017-0529-x
- Moorkens E, Lacosta TB, Dawoud D, et al. A systematic literature review of gaps and challenges in value assessment of biosimilars: an ISPOR special interest group report. Value Heal. 2023 Aug;26(8):1137–1144.
- Mack A. Norway, biosimilars in different funding systems. What works? Generics Biosimilars Initiat J. 2015 Jun;4(2):90–92. doi: 10.5639/gabij.2015.0402.018
- Jensen TB, Kim SC, Jimenez-Solem E, et al. Shift From Adalimumab Originator to Biosimilars in Denmark. JAMA Intern Med. 2020;180(6):902–903. doi: 10.1001/jamainternmed.2020.0338
- Barcina Lacosta T, Vulto AG, Turcu-Stiolica A, et al. Qualitative analysis of the design and implementation of benefit-sharing programs for biologics across Europe. BioDrugs. 2022 Mar;36(2):217–229. doi: 10.1007/s40259-022-00523-z
- Blackstone EA, Joseph PF. The economics of biosimilars. Am Heal Drug Benefits. 2013 Sep;6(8):469–478.
- Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Heal Q. 2018 Mar;7(4):3.
- Fein AJ, “The Big three PBMs’ 2023 formulary exclusions: observations on Insulin, Humira, and Biosimilars,” 2023. [cited 2023 Nov 6]. Available from: https://www.lipa.org/post/the-big-three-pbms-2023-formulary-exclusions-observations-on-insulin-humira-and-biosimilars
- Tenni B, Moir HVJ, Townsend B, et al. What is the impact of intellectual property rules on access to medicines? A systematic review. Global Health. 2022 Apr;18(1):40.
- Vincent Rajkumar S. The high cost of prescription drugs: causes and solutions. Blood Cancer J. 2020 Jun;10(6):71. United States. doi: 10.1038/s41408-020-0338-x
- Biosimilars Development, “Multi-stakeholder workshop on biosimilar medicines a crucial milestone in achieving increased patient access to biological therapies,” 2018. [cited 2023 Dec 13]. Available from: https://www.biosimilardevelopment.com/doc/multi-stakeholder-biosimilar-crucial-milestone-increased-patient-access-biological-therapies-0001
- Commision E, “Corporate responsibility in the pharmaceutical industry.” 2017 [accessed 2024 Jan 12]. Available from: https://single-market-economy.ec.europa.eu/corporate-responsibility-pharmaceutical-industry_en